Overview
Leber hereditary optic neuropathy (LHON) is a mitochondrial disorder characterized by bilateral vision loss, typically affecting young adults, due to mutations in mitochondrial DNA 1.Diagnosis
Genetic Testing: Identification of one of three primary mitochondrial DNA mutations (m.11778G>A, m.3460G>A, m.14484T>C) 1.
Clinical Presentation: Sudden onset of painless, usually asymmetric, visual loss in young adulthood 1.
Ophthalmologic Examination: Optic disc swelling (papilledema) in early stages, followed by optic atrophy 1.
Visual Acuity Testing: Significant reduction in visual acuity, often measured using Snellen charts 1.
Electrophysiological Tests: Visual evoked potentials (VEP) may show delayed latency and reduced amplitude 1.
Fundus Photography: Documentation of optic disc changes over time 1.Management
First-Line Treatment: Idebenone (Raxone) has been approved for LHON; dosing typically starts at 900 mg twice daily 1.
Adjunctive Therapies: No other specific adjunctive therapies are widely recommended based on current evidence 1.
Supportive Care: Includes low vision aids, visual rehabilitation, and psychological support 1.Special Populations
Pregnancy: Management considerations during pregnancy are not specifically addressed in the provided abstracts 1.
Pediatrics: LHON typically presents in young adulthood; pediatric cases are rare and not detailed in the abstracts 1.
Elderly: LHON is uncommon in elderly populations due to its typical age of onset 1.
Comorbidities: Specific management adjustments for comorbidities are not discussed in the abstracts 1.Key Recommendations
Genetic Counseling and Testing: Essential for confirming diagnosis and assessing risk in family members (Evidence: Expert opinion) 1.
Early Initiation of Idebenone: Consider starting idebenone early in the disease course, ideally within months of symptom onset, to potentially mitigate visual loss (Evidence: Expert opinion) 1.
Monitoring and Follow-Up: Regular ophthalmologic evaluations and visual function assessments are crucial for monitoring disease progression and treatment efficacy (Evidence: Expert opinion) 1.References
1 Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagrèze WA et al.. International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2017. link
2 Blum M, Hykin PG, Sanders M, Völcker HE. Theodor Leber: a founder of ophthalmic research. Survey of ophthalmology 1992. link90006-f)